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The synthesis and spectral characterization of novel diorganotin complexes with 3-hydroxypyridine-2-carbaldehyde thiosemicar-
bazone, H2L( 1 ) ,[ S n M e 2(L)] (2),[ S n B u 2(L)] (3), and [SnPh2(L)] (4) are reported. The single-crystal X-ray structure of complex
[SnPh2(L)(DMSO)] (5) shows that the ligand is doubly deprotonated and is coordinated as tridentate ligand. The six coordination
number is completed by two carbon atoms of phenyl groups. There are two similar monomers 5a (Sn1) and 5b (Sn51) in the
asymmetric unit. The monomers 5a and 5b are linked through intermolecular hydrogen bonds of N–H–O and C–H–S type.
C–H → π, intermolecular interactions, intra- and intermolecular hydrogen bonds stabilize this structure and leads to aggregation
and a supramolecular assembly. The IR and NMR (1H, 13Ca n d119Sn) spectroscopic data of the complexes are reported. The in
vitro cytotoxic activity has been evaluated against the cells of three human cancer cell lines: MCF-7(human breast cancer cell line),
T-24 (bladder cancer cell line), A-549 (nonsmall cell lung carcinoma) and a mouse L-929 (a ﬁbroblast-like cell line cloned from
strain L). Compounds 1, 3,a n d4 were found active against all four cell lines. Selectivity was observed for complexes 3 and 4 which
were found especially active against MCF-7 and T-24 cancer cell lines.
1.Introduction
Organotin(IV) compounds ﬁnd wide applications as cat-
alysts and stabilizers, and certain derivatives are used as
biocides, as antifouling agents and for wood preservation.
It has been observed that several diorganotin adducts show
potential as antineoplastic and antituberculosis agents [1–4].
Thiosemicarbazone derivatives are of considerable inter-
est due to their antibacterial, antimalarial, antiviral, and
antitumor activitiy [5, 6]. In our laboratory, the chemistry
of thiosemicarbazones has been an extremely active area
of research, primarily because of the beneﬁcial biologi-
cal (namely, antiviral and antitumor) activities of their
transition-metal complexes [7–9]. 3-Hydroxypyridine-2-
carbaldehyde thiosemicarbazone (1) is a member of the so-
called α-(N)-heterocyclic carbaldehyde thiosemicarbazones
(HCTs), which are the most potent known inhibitors of
ribonucleoside diphosphate reductase. Compounds (1)a n d
5-hydroxypyridine-2-carbaldehyde thiosemicarbazone have
shown high anticancer activity in animal models but were
found to be readily glucuronidated and rapidly excreted
[10]. The multiple dissociation constants of the ligand H2L
(1) and the crystal structure of he complex of Pd(II) with
1,[ P d ( H L ) C l ]h a v eb e e ns t u d i e db yu s[ 11]. This work is
an extension of previously studied complexes of thiosemi-
carbazones with palladium(II), platinum(II), zinc(II), and
organotin(IV) with potentially interesting biological activi-
ties [12–14].
The present paper includes the interaction of SnPh2O
(where R is methyl, butyl, and phenyl groups) with 3-
Hydroxypyridine-2-carbaldehyde thiosemicarbazone (H2L)
and the crystal structure of the complex [SnPh2(L)(DMSO)]2 Bioinorganic Chemistry and Applications
(5).IRandNMRspectroscopicdataarereported.Theresults
of the cytotoxic activity of diorganotin complexes have been
evaluatedforantiproliferativeactivityinvitroagainsthuman
cancer cell lines: MCF-7, T-24, A-549, and a mouse L-929.
2. Experimental
2.1. General and Instrumental. A l lr e a g e n t sw e r ec o m m e r -
cially available (Aldrich or Merck) and used as supplied.
Solvents were puriﬁed and dried according to standard
procedures. Melting points (m.p.) were determined in open
capillaries and are uncorrected. IR and far-IR spectra were
recorded on a Perkin Elmer Spectrum GX Fourier transform
spectrophotometer using KBr pellets (4000–400cm−1)a n d
nujol mulls dispersed between polyethylene disks (400–
40cm−1). The free ligand was dissolved in (CD3)2SO and
1H, 1H–1HC O S Ya n d13Cs p e c t r aw e r ea c q u i r e do na
BRUKER 300MHz spectrometer. Compounds 2–4 were
dissolved in CDCl3 and were spectroscopically characterized
by the use of 1Da n d2D NMR spectroscopy on a Varian
600 MHz spectrometer. Experimental data were processed
using VNMR and WinNMR routines. Chemical shifts (δ)
are reported in ppm while spectra were referenced by
the standard experimental setup. 119Sn NMR spectra were
acquired on the Varian 600MHz and tin spectra were
referenced by the use of external solution of Me4Sn in C6D6.
The splitting of proton resonances in the reported 1H-NMR
spectra is deﬁned as s = singlet, d = doublet, t = triplet, and
m = multiplet. The chemical shifts are reported in ppm for
1Ha n d13C NMR. Elemental analyses were carried out by the
microanalyticalserviceoftheUniversity ofIoannina,Greece.
2.2. Synthesis of the Ligand and the Complexes
3-Hydroxypyridine-2-Carbaldehyde Thiosemicarbazone (1).
The ligand was synthesized according to a published pro-
cedure [11]. The white powder was recrystallized from
cold ethanol and was dried in vacuo over silica gel.
Yield: 75%. Bright-yellow powder. M.p. 209◦C. IR (cm−1):
3555s, 3451m v(OH); 3291m, 3194m, v(NH2, NH); 1639s,
v(C=N); 1229s, v(C–O); 1098s, v(NN); 827s, v(C=S). 1H-
NMR: 11.50 (s, OH); 9.62 (s, H–N(3); 8.12 (d, H–C(1), 3J
= 4.2Hz); 7.26 (dd, H–C(2) 3J = 8.5, 4J = 4.2Hz); 7.30 (dd,
H–C(3) 3J = 8.4, 4J = 1.4Hz); 8.34 (s, H–C(6)); 8.00, 8.24
(br. s, NH2). 13C-NMR: 178.0 C(7); 153.1 C(4); 144.4 C(6);
141.1C(1);137.6C(5);125.3C(2);124.2C(3).Anal.calc.for
C7H8N4OS (196.04): C, 42.8; H, 4.1; N, 28.6; S, 16.3; found:
C, 42.6; H, 3.9; N, 28.2; S, 16.0%.
SnMe2(L) (2). Dimethyltin(IV) oxide (0.033g, 0.2 mmole)
and 3-hydroxypyridine-2-carbaldehyde Thiosemicarbazone
(0.0392g, 0.2 mmole) in benzene (20mL) were stirred and
were reﬂuxed for 12hours under azeotropic removal of water
(Dean-Stark trap). The resulting clear solution was rotary
evaporated under vacuum to a small volume (2mL), chilled
and triturated with diethyl ether to give a white solid. The
powder was recrystallized from distilled diethyl ether and
dried in vacuo over silica gel to give yellow solid; mp.
228–230◦C, Yield 35%. IR (cm−1): 3296m, v(NH2); 1580s,
v(C=N); 1176s, v(C–O); 1111s, v(NN); 804w, v(C=S);
583m, 564 v(Sn–C); 431m, v(Sn–N); 231m, v(Sn–O); 376s,
ν(Sn–S). 1H-NMR: 8.09 (dd, H–C(1), 3J = 4.2,4J = 1.4Hz);
7.18 (dd, H–C(2) 3J = 8.5, 4J=4.2Hz); 7.08 (d, H–C(3) 3J
= 8.5,4J = 1.4 Hz); 8.76 (s, H–C(6)); 5.09 (br. s, NH2); 0.89
(s, CH3, 2J( 117/119Sn–1H) = 35.7Hz). 13C-NMR: 168.8 C(7);
163.4 C(4); 161.5 C(6); 140.2 C(1); 135.4 C(5); 127.6 C(2);
128.9 C(3); 6.22 (CH3,J( 117/119Sn–13C) = 309Hz). 119Sn
NMR: δ = −94.5. Anal. calc. for C9H12N4OSSn (343.0): C,
31.5; H, 3.5; N, 16.3; S, 9.3; found: C, 31.5; H, 3.7; N, 16.0;,
S, 9.1 %.
SnBu2(L) (3). Dibutylltin(IV) oxide (0.0498g, 0.2 mmole)
and 3-hydroxypyridine-2-carbaldehyde Thiosemicarbazone
(0.0392g, 0.2 mmole) in benzene (20mL) were stirred and
were reﬂuxed for 12hours under azeotropic removal of water
(Dean-Stark trap). The resulting clear solution was rotary
evaporated under vacuum to a small volume (2mL), chilled
and triturated with diethyl ether to give a white solid. The
powder was recrystallized from distilled diethyl ether and
dried in vacuo over silica gel to give yellow solid; mp.
126–128◦C, Yield 41%. IR (cm−1): 3292m, v(NH2); 1577s,
v(C=N); 1173s, ν(C–O); 1114s, v(NN); 805w, ν(C=S);
578ms, 560shν(Sn–C); 418m, ν(Sn–N); 247m, ν(Sn–O);
394ms, ν(Sn–S). 1H-NMR: 8.05 (dd, H–C(1), 3J = 4.2, 4J =
1.3Hz); 7.16 (dd, H–C(2) 3J = 8.5, 4J = 4.2Hz); 7.07 (dd, H-
C(3) 3J =8.5, 4J =1.3Hz);8.82(s,H-C(6));5.22(br.s,NH2);
0.87 (t, 7.3Hz, Hδ); 1.32 (m, Hγ); 1.54, 1.64 (Hα,β). 13C-
NMR: 167.7 C(7); 162.5 C(4); 160.0 C(6); 138.7 C(1); 134.5
C(5); 126.8 C(2); 128.0 C(3); 26.9 (Cα,J( 117/119Sn−13C) =
265Hz); 28.2 (Cβ); 27.3 (Cγ); 14.6 (Cδ). 119Sn NMR: δ =
−194.4. Anal. calc. for C16H18N4OSSn (537.2): C, 42.2; H,
5.7; N, 13.1; S, 7.5; found: C, 42.0; H, 5.9; N, 13.2; S, 7.4 %.
SnPh2(L) (4). Diphenylltin(IV) oxide (0.0578g, 0.2mmole)
and 3-hydroxypyridine-2-carbaldehyde thiosemicarbazone
(0.0392g, 0.2 mmole) in benzene (20mL) were stirred and
were reﬂuxed for 12 hours under azeotropic removal of
water (Dean-Stark trap). The resulting clear solution was
rotary evaporated under vacuum to a small volume (2mL),
chilled and triturated with diethyl ether to give a white solid.
The powder was recrystallized from distilled diethyl ether
and dried in vacuo over silica gel to give yellow solid:mp.
186–188◦C, Yield 34%. IR (cm−1): 3269m, ν(NH2); 1589s,
ν(C=N); 1185s, v(C–O); 1118s, v(NN); 808m, v(C=S);
322ms, 303sh ν(Sn–C); 419m, ν(Sn–N); 248m, ν(Sn–O);
370ms, ν(Sn–S). 1H-NMR: 8.02(d, H–C(1), 3J = 4.2Hz);
7.18(dd, H-C(2), 3J = 8.5, 4J = 4.2Hz); 7.29 (d, H-C(3),
3J = 8.5Hz); 8.88 (s, H–C(6)); 5.37 (br. s, NH2); 7.82 (d,
7.7Hz, Ho-Ph); 7.34–7.30 (m, Hm, p-Ph). 13C-NMR: 167.4
C(7); 164.0 C(4); 161.5 C(6); 140.2 C(1); 135.4 C(5); 127.8
C(2);129.3 C(3); 142.1 (Sn-Cph, J (117/119Sn–13C) = 424Hz);
135.8 (Co-Ph, 2J( 117/119Sn–13C) = 28Hz); 128.8 (Cm-Ph,
3J( 117/119Sn–13C) = 37Hz); 130.2 (Cp-Ph, 4J( 117/119Sn–
13C) = 8.7Hz); 119Sn NMR: δ = −227.2. Anal. calc. for
C19H16N4OSSn (663.1): C, 48.9; H, 3.5; N, 12.0; S, 6.9;
found: C, 48.6; H, 3.5; N, 10.7; S, 6.8%.Bioinorganic Chemistry and Applications 3
Table 1: X-ray crystal data and structure reﬁnement.
5
Empirical formula C21H22N4O2S2Sn
Formula weight 545.24
Temperature/ (K) 100 (2)
Wavelength/ (A) 0.71073
Crystal system Triclinic
Space group P-1
a (˚ A) 9.4663 (4)
b (˚ A) 14.7350 (7)
c (˚ A) 16.6374 (7)
α (◦) 94.871 (4)
β (◦) 96.434 (4)
γ (◦) 90.793 (4)
Volume (A
3) 2297.1 (2)
Z 4
Dc (Mg/m3) 1.577
Absorption coeﬃcient (mm−1) 1.319
F(000) 1096
Crystal size (mm) 0.32 ×0.28 ×0.16
Diﬀractometer Kuma KM4CCD
Theta range for data collection (◦) 3.14–36.65
Ranges of h, k, l −15→15, −24→20, −27→27
Reﬂections collected 35235
Independent reﬂections (Rint) 18670 (0.0381)
Completeness to 2θ = 36.65 81.9%
Data/parameters 18670/541
Goodness-of-ﬁt (F2) 0.920
Final R1/wR2 indices [I>2σ(I)] 0.0336/0.0768
Largest diﬀ. peak/hole (e/˚ A3) 2.090/−1.098
2.3. X-Ray Crystallography. Crystals of complex 5, suitable
for X-ray analysis, were obtained by slow crystallization of
4 from a mixture of solvents C6H6/toluene/DMSO/CH3CN.
Crystal data 5 are given in Table 1, together with reﬁnement
details. All measurements of crystals were performed in
low temperature using an Oxford Cryosystem device on
aK u m aK M 4 C C Dκ-axis diﬀractometer with graphite-
monochromated Mo Ka radiation. The data were corrected
for Lorentz and polarization eﬀects. No absorption correc-
tion was applied. Data reduction and analysis were carried
out with the Oxford Diﬀraction (Poland) Sp. z o.o (formerly
Kuma DiﬀractionWroclaw,Poland)programs.Crystalstruc-
ture wassolved by direct methods (program SHELXS97) and
reﬁnedbythefull-matrixleast-squaresmethodonallF2 data
using the SHELXL97 [15] programs. Nonhydrogen atoms
were reﬁned with anisotropic displacement parameters;
hydrogen atoms were included from geometry of molecules
and Δρ maps. During the reﬁnement process they treated
as riding atoms. Molecular graphics were performed from
PLATON2003 [16, 17].
Crystallographic data, that is, atomic coordinates, ther-
mal parameters, bond lengths, and bond angles (CCDC
number 634270 for 5), have been deposited with the
CambridgeCrystallographicDataCentre.Copiesofavailable
material can be obtained, free of charge, on application
to CCDC, 12 Union Road, Cambridge CB2 1EZ, UK,
(fax:+44-1223-336033ore-mail:deposit@ccdc.cam.ac.ukor
http://www.ccdc.cam.ac.uk).
2.4. Antiproliferative Assay In Vitro. The results of cytotoxic
activity in vitro are expressed as IC50-the concentration of
compound (in μM) that inhibits a proliferation rate of the
tumor cells by 50% as compared to control untreated cells.
The compounds 1–4 were tested for their antiproliferative
activity in vitro against the cells of four human cancer cell
lines: against the cells of three human cancer cell lines: MCF-
7 (human breast cancer cell line), T-24 (bladder cancer cell
line), A-549 (nonsmall cell lung carcinoma), and a mouse
ﬁbroblast L-929 cell line.
Compounds. Test solutions of the compounds tested
(1mg/mL) were prepared by dissolving the substance in
100μL of DMSO completed with 900μLo ft i s s u ec u l t u r e
medium. Afterwards, the tested compounds were diluted
in culture medium to reach the ﬁnal concentrations of
100, 50, 10, 1 and 0.1ng/μL. The solvent (DMSO) in
the highest concentration used in test did not reveal any
cytotoxic activity. Cells. The cell lines are maintained in
the Cell Culture Collection of the University of Ioannina.
Twenty-four hours before addition of the tested agents,
the cells were plated in 96-well plates at a density of 104
cells per well. The MCF-7 cells were cultured in the D-
MEM (Modiﬁed Eagle’s Medium) medium supplemented
with 1% antibiotic and 10% fetal calf serum. L-929 cells
w e r eg r o w ni nH e p e s - b u ﬀered RPMI 1640 medium sup-
plemented with 10% fetal calf serum, penicillin (50U/mL),
and streptomycin (50mg/mL). A-549 cells were grown in
F-12K Ham’s medium supplemented with 1% glutamine,
1% antibiotic/antimycotic, 2% NaHCO3, and 10% fetal calf
serum. The cell cultures were maintained at 37◦Ci na
humid atmosphere saturated with 5% CO2.C e l ln u m b e r
was counted by the Trypan blue dye exclusion method.
MCF-7, L-929, and A-549 cells were determined by the
sulforhodamine B assay [18], while T-24 cells by the MTT
assay [19]. The in vitro tests were performed as described
previously [20].
3. Results and Discussion
3.1. Spectroscopy
3.1.1. Infrared Spectroscopy. The bands at 3555 and
3451cm−1 are assigned to v(OH) mode while the medium-
strong intensity bands at around 3291 and 3194cm−1 in
the spectra of H2L are assigned to v(NH2)a n dv(NH),
respectively. The signiﬁcant changes in the ligand bands
upon complexing are the decrease in ν(C=N) and increase
in ν(N–N) and the absence of the large systematic shifts
of νas(NH2) to lower frequencies. These data indicate
coordination through the nitrogen of the azomethine group
and no interaction between the terminal amino nitrogen
and the metal ion. The ν(CS) band at 827cm−1is less intense4 Bioinorganic Chemistry and Applications
in the complexes 2–4 and is shifted to a lower frequency,
suggesting coordination of the metal through sulfur.
Coordination of the thiolato S-atom was further indicated
by a decrease in the energy of the thioamide band as well
as by the presence of a band at ca. 370cm−1 assignable to
ν(Sn–S). An IR band at 1229cm−1 for 1 was assigned to ν(C–
O). This band was found to be shifted to 1185–1173cm−1,
in the spectra of the complexes 2–4. Coordination of the
phenolic-O atom was further indicated by the presence of
a band at ca. 250–230cm−1 assignable to ν(Sn–O). From
the metal-ligand stretching vibrations, which are below
600cm−1, it is possible to assign the bands characteristic for
ν(SnC). Also, the bands at 394–370cm−1and 431–418cm−1
are assigned to ν(SnS) and ν(SnN), respectively, and the
bands at 250–230 cm−1 are assigned at ν(SnO) stretching
vibrations [20, 21].
3.1.2. NMR Spectra. 1Ha n d13C resonances of the ligand
H2L as well as of the complexes 2–4 bearing di-methyl, n-
butyl, and phenyl groups attached to the central tin atom
were unambiguously assigned by the use of 2D 1H-1H
gCOSY, 1H, 13C-HSQC, and 1H, 13C-HMBC experiments.
In the 1H NMR spectra of (H2L) (1) the broad singlet
at δ 11.60 was attributed to OH group in accordance with
[22] and the broad signal at δ 9.75ppm was assigned to
NH group. These two groups apparently participate in H-
bonding with the nucleophilic solvent molecules (DMSO) or
with other ligand molecules. These two signals are abolished
upon interaction with the metal, indicating deprotonation
of these groups and possible coordination to the tin(IV)
atom at 2–4. The absence of peaks corresponding to the
imino proton NH and OH proton in the spectrum of 2–
4 indicates that the nitrogen and oxygen are present in the
deprotonatedformandtheligandisdideprotonated.Asharp
resonance peak appearing at ca. 5ppm in all complexes
is attributed to the NH2 group. This is also corﬁrmed by
integration of the 1H spectral proﬁle while additionally the
use of CDCl3 eliminates the formation of H-bonding or
complexation with the participation of solvent molecules
as was the case with the ligand alone. In the 1H-NMR
spectra of the complexes 2–4, the formyl H-atom H–C(6)
was shifted upon coordination, which indicated variations
in the electron density at position 6. This signal was shifted
downﬁeld, in accordancewitha decreased electrondensity at
site C6 in the complexes.
The C=S resonance of the thiosemicarbazone moiety in
thefreeligandresonatedat178.0ppm.Allcomplexesshowed
anupﬁeldshiftofC7peakintheorderof∼10ppmcompared
with the free ligand, indicating the complexation of tin(IV)
to the sulphur atom which apparently is related with an
increased electron density at this site on complexation, due
probably to π-back bonding for thiolato sulphur [21]. All
the complexes exhibit downﬁeld shifts of the C3, C4, and
C6. This deshielding, in accordance with decreased electron
density upon complexation, is indicative of Sn–O and Sn–
N (azomethine nitrogen) bonds. These data indicate that the
complexes are formed by ligand deprotonation followed by
metallation, a structural motive that seems to be stable both
in the solid state and in CDCl3 solution. 119Sn chemical shifts
of compounds 2–4 were found between −94.4 and −227.2 in
accordance with ﬁve-coordinate tin center [23].
3.2. Molecular Structure. Crystals of complex 5,s u i t a b l ef o r
X-ray analysis, were obtained by slow crystallization of 4
from a mixture of solvents C6H6/toluene/DMSO/CH3CN.
The crystal structure is shown in Figure 1. Crystal data are
given in Table 1, together with reﬁnement details. Bond
lengths and angles are given in Table 2. There are two similar
monomers 5a (Sn1) and 5b (Sn51) in the asymmetric unit.
The double deprotonated ligand is coordinated as tridentate
ligand via the phenolic oxygen O(1), the azomethine nitro-
gen N(3), and thiolato sulfur S(1) atoms. The molecule of
DMSO is coordinated to the tin through oxygen O(2) atom.
The six coordination number is completed by two carbon
atomsofphenylgroups.Theorganicmoleculeactsasanionic
tridentate with the ONS donors placed in the same side. The
dianionic, tridentate ligand has a ZEZ conﬁguration for the
oxygen, nitrogen, and sulfur donor centers. The coordinated
ligand consists of three rings, one heterocyclic and two
chelates, SnSNNC and SnONCC, I and II, respectively. For
monomers 5a and 5b the dihedral angles between the planes
of the rings I and II are 14.47(6) and 12.59(6)◦,r e s p e c t i v e l y
and between the ring II and the pyridyl ring are 7.4(5) and
8.1(2)◦, respectively, indicating that the ligand as a whole in
the two monomers deviates from planarity.
The C–S bond lengths 1.747(2), 1.749(2) ˚ Af o r5a and
5b, respectively, are shorter than a single bond (1.81 ˚ A), but
longer than a double bond (1.62 ˚ A), suggesting partial single
bond character. The C(14)–N(3) bond length, 1.301(2) ˚ A, is
close to a double bond (1.28 ˚ A). The S–C bond distances
are consistent with increased single-bond character while
both thioamide C–N distances indicate increased double
bond character. The negative charge of the deprotonated
ligand is delocalized over the thiosemicarbazonato moiety.
This is indicative of the coordinated thiosemicarbazone’s
greater conjugation and more delocalized electron density.
The Sn–N(3) bond distance is longer than the sum of the
covalent radii (2.15 ˚ A), which indicates strong bond, while
the bond distance Sn–S, 2.5141(5), 2.519(5) ˚ A, though much
shorter than the sum of the van der Waals radii (4.0 ˚ A),
indicates a weak bond [21]. The C–SnC bond angle is equal
to 105.87(7), 104.58(7)◦, and the bond angles C(7)–Sn–N(3)
and C(1) –Sn–O(2) are 160.47(6), 165.59(6) and 162.80(6),
166.89(6)◦ for 5a and 5b,r e s p e c t i v e l y .
The two monomers 5a and 5b are linked through two
intermolecular hydrogen bonds of N(51)–H(51B)–O(1) and
of C(8)–H(8)–S(51) type (The N–O distance is 3.013(2) ˚ A
and the C–S distance is 3.673(2) ˚ A. The monomers of
5a form hydrogen-bonded dimers linked by two N(1)–
H(1A)–N(4) hydrogen bonds involving the amino N(1)–
H(1A) hydrogen atom and the pyridyl N(4) nitrogen. The
monomers of 5a are also linked by another C(14)–H(14)–
N(2) hydrogen bond involving the formyl C(14)–H(14)
hydrogen and the adjacent imino nitrogen N(2) and vice
versa of centro-symmetrically related pairs of molecules.
The observed hydrogen bonding patterns are of the DA=ADBioinorganic Chemistry and Applications 5
C54
C53
C55
C56
C52 C51 C66
C65 C64
C69 C68
N54
N53
N51
N52
Sn51
C63
C58
C59
O52
O51
C62 C57
C60 S52
C70
C71
C61
S51
C67
(a)
C21
C20
S2
C11
O2
C12
C10
C9
C8 C7
Sn1
N3
N2
S1
C13
N1
C15 O1
C14
C1 C2
C6
N4
C19
C18
C16
C17
C5 C4
C3
(b)
Figure 1: Molecular structure of the diorganotin complex 5.
Table 2: Bond lengths (˚ A) and angles (◦)f o rc o m p l e x5 .
5a 5b
Sn(1)–S(1) 2.5141(5) Sn(51)–S(51) 2.5190(5)
Sn(1)–O(1) 2.087(2) Sn(51)–O(51) 2.088(2)
Sn(1)–O(2) 2.337(2) Sn(51)–O(52) 2.345(2)
Sn(1)–N(3) 2.251(2) Sn(51)–N(53) 2.262(2)
Sn(1)–C(1) 2.164(2) Sn(51)–C(51) 2.157(2)
Sn(1)–C(7) 2.149(2) Sn(51)–C(57) 2.151(2)
S(1)–C(13) 1.747(2) S(51)–C(63) 1.749(2)
S(2)–O(2) 1.528(2) S(52)–O(52) 1.528(2)
S(2)–C(20) 1.791(3) S(52)–C(70) 1.777(3)
S(2)–C(21) 1.789(2) S(52)–C(71) 1.787(3)
O(1)–C(19) 1.326(2) O(51)–C(69) 1.320(2)
N(2)–N(3) 1.380(2) N(52)–N(53) 1.375(2)
S(1)–Sn(1)–O(1) 156.25(4) S(51)–Sn(51)–O(51) 155.68(4)
S(1)–Sn(1)–O(2) 84.87(3) S(51)–Sn(51)–O(52) 83.23(3)
S(1)–Sn(1)–N(3) 77.37(4) S(51)–Sn(51)–N(53) 77.71(4)
S(1)–Sn(1)–C(1) 101.71(5) S(51)–Sn(51)–C(51) 100.07(5)
S(1)–Sn(1)–C(7) 95.51(5) S(51)–Sn(51)–C(57) 100.30(5)
O(1)–Sn(1)–O(2) 76.08(5) O(51)–Sn(51)–O(52) 77.25(5)
O(1)–Sn(1)–N(3) 84.11(5) O(51)–Sn(51)–N(53) 83.46(5)
O(1)–Sn(1)–C(1) 94.05(6) O(51)–Sn(51)–C(51) 95.98(6)
O(1)–Sn(1)–C(7) 97.14(6) O(51)–Sn(51)–C(57) 93.14(6)
O(2)–Sn(1)–N(3) 75.34(5) O(52)–Sn(51)–N(53) 75.65(5)
O(2)–Sn(1)–C(1) 165.59(6) O(52)–Sn(51)–C(51) 166.89(6)
O(2)–Sn(1)–C(7) 86.01(6) O(52)–Sn(51)–C(57) 87.15(6)
N(3)–Sn(1)–C(1) 93.44(6) N(53)–Sn(51)–C(51) 92.55(7)
N(3)–Sn(1)–C(7) 160.47(6) N(53)–Sn(51)–C(57) 162.80(6)
C(1)–Sn(1)–C(7) 105.87(7) C(51)–Sn(51)–C(57) 104.58(7)6 Bioinorganic Chemistry and Applications
Figure 2: Arrangement of the intermolecular hydrogen bonds in 5.
Table 3: C–H→ π interactions and intermolecular hydrogen bonds for 5.
C–H(I) → Cg(J)
a H–Cg C–Cg ∠C–H–Cg
C(11)–H(11) [1] → Cg(4)
(i) 2.71 3.5394 159
C(60)–H(60) [2] → Cg(5)
(ii) 2.66 3.4118 135
DH A
b H ··· AD ··· A ∠D–H ··· A
N(1)–H(1A)···N(4)
(iii) 2.13 3.005(2) 165
N(1)–H(1B)···O(51)
(iv) 2.28 3.065(2) 150
N(1)–H(1B)···O(52)
(iv) 2.55 3.124(2) 124
N(51)–H(51A)···N(54)
(v) 2.16 2.993(3) 168
N(51)–H(51B)···O(1) 2.24 3.013(2) 152
C(8)–H(8)···S(51) 2.84 3.673(2) 143
C(14)–H(14)···N(2)
(iii) 2.50 3.442(2) 175
C(58)–H(58)···S(51) 2.85 3.564(2) 127
C(62)–H(62)···O(51) 2.55 3.132(2) 118
C(64)–H(64)···N(52)
(v) 2.58 3.483(2) 174
aWhere Cg(4) and Cg(5) are referred to the rings C(1)–C(6) and C(7)–C(12); bCg–Cg is the distance between ring centroids; symmetry transformations, (i)
1 −x, −y, −z; (ii) 1−x,1 −y, −z; (iii) 1−x, −y,1−z;( i v )x, −1+y, z;( v )2−x,1− y,1−z.
type. Also, the monomers of 5b form hydrogen-bonded
dimers and are linked by two hydrogen bonds, the N(51)–
H(51A)–N(54) and C(64)–H(64)–N(52) (Figure 2). C–H→
π intermolecular interactions intra- and intermolecular
hydrogen bonds [24] stabilize this structure and lead to a
supramolecular assembly, and Table 3 and Figure 3.
3.3. Pharmacology. Antiproliferative Activity In Vitro. Com-
plexes of N4-ethyl 2-acetylpyridine thiosemicarbazone with
platinum(II) or palladium(II) were tested in a panel of
human tumor cell lines of diﬀerent origins (breast, colon,
and ovary cancers) and cis-platin-refractory/resistant cell
lines and were found to exhibit very remarkable growth
inhibitory activities with mean IC50 values of 0.9–0.5nM
and support the hypothesis that both [Pt(Ac4Et)2]a n d
[Pd(Ac4Et)2] complexes can be characterized by cellular
pharmacological properties distinctly diﬀerent from those
of cis-platin [8]. The complexes [ZnCl2(Fo4Npypipe)] and
[ZnCl2(Ac4Npypipe)] where Fo4Npypipe and Ac4Npypipe
are the monoion of 2-formyl pyridine N(4)-1-(2-pyridyl)-
piperazinyl thiosemicarbazone and 2-acetyl pyridine N(4)-
1-(2-pyridyl)-piperazinyl thiosemicarbazone havebeen eval-
uated in vitro against MCF-7, T-24, A-549, and L-929 cellBioinorganic Chemistry and Applications 7
Figure 3: A view of the extended network of 5 along the b axis.
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Figure 4: The antiproliferative activity in vitro expressed as IC50± SD (μM) against (a) T-24 and (b) MCF-7 cancer cell lines.8 Bioinorganic Chemistry and Applications
Table 4: The antiproliferative activity in vitro of 1–4, expressed as as IC50 ±SD (μM) against MCF-7, T-24, A-549, and L-929 cancer cell
lines.
L929 A549 T24 MCF7
H2L( 1 ) 2.5 ±0.03 0.81± 0.02 2.09 ±0.03 0.153 ±0.01
[SnMe2(L)] (2)7 .29 ±0.04 9.04 ± 0.05 <292 0.79 ±0.03
[SnBu2(L)] (3)1 .05 ±0.02 0.77 ±0.03 1.1 ± 0.05 1.97 × 10
−2 ±0.2 ×10
−2
[SnPh2(L)] (4)1 .37 ±0.03 0.83 ±0.02 0.73 ± 0.02 7.28 × 10−2 ±0.5 ×10
−2
Me2SnO <607 17.9 ± 0.86 <607 6.0 ×10−2 ±0.2 ×10
−2
Bu2SnO <402 10.4 ± 0.41 <402 8.1 ×10−2 ±0.4 ×10
−2
Ph2SnO 10.7 ±0.54 7 .1 ±0.49 <346 3.5 ± 0.02
cisplatin 0.69 ±0.03 1.53 ±0.10 41.66 ± 2.27 .99 ±0.31
lines and it was found to exhibit remarkable antiproliferative
activity with mean IC50 values of 0.2–20μM[ 12]. The
diphenylorganotin(IV) complex with pyruvic acid thiosemi-
carbazone has been tested against MCF-7, T-24, A-549, and
L-929 cell lines and was found especially active against MCF-
7 and T-24 cancer cells [21].
The antiproliferative activity of compounds is presented
in Table 4 along with the activity of cis-platin and diorgan-
otin(IV) oxides. Results showed that the ligand as well as the
complexes 3 and 4 demonstrated excellent antiproliferative
activity, IC50 values range from 0.02–2.5μM, against all
cell lines tested, while for cis-platin the IC50 values range
from 0.7–41 μM. The diorganotin(IV) oxides are nontoxic
against L-929 and T-24 cancer cell lines and exhibit poor
cytotoxic activity in A-549 and excellent antiproliferative
activity against MCF-7 cancer cell line.
The ligand 1 is more cytotoxic compared to cis-platin
against the A-549, T-24 and MCF-7 cell lines and less
cytotoxic against L-929 cell lines. The diorganotin complex
2 is nontoxic against T-24 cell line, less cytotoxic against
A-549 and L-929, and more cytotoxic against MCF-7 cell
line compared to cis-platin. The diorganotin complexes 3
and 4 are in the same μM range compared to cis-platin
against L-929 and A-549 cancer cell lines and more cytotoxic
against T-24 and MCF-7 cancer cell lines. The IC50 values
for the ligand, 1, against MCF-7 and T-24 cell lines are 0.15
μM and 2.09μM, respectively, and against A-549 and L-
929 cell lines are 0.81μMa n d2 . 5μM, respectively. Ligand
is 19.8 ± 1.3 and 52.4 ± 4.6 times more active than cis-
platin against T-24 and MCF-7 cell lines, respectively. The
IC50 values for 3 against MCF-7 and T-24 cell lines are
1.97 × 10
−2μMa n d1 . 1μM, respectively, and against A-549
and L-929 cell lines are 0.77μM and 1.05μM, respectively.
Complex 3 is 403.6 ± 20.2 times more active than cis-platin
against MCF-7 cell line and 37.9 ± 3.1 times more active
than cis-platin against T-24 cell line. The IC50 values for
4 against MCF-7 and T-24 cell lines are 7.28 × 10
−2μM
and 0.73μM, respectively, and against A-549 and L-929
cell lines are 0.83μM and 1.37μM, respectively. Complex
4 is 110.3 ± 9.9 times more active than cis-platin against
MCF-7 cell line and 57.1 ± 3.9 times more active than
cis-platin against T-24 cell line. Compounds 1, 3,a n d4
were found active against all four cell lines. Selectivity
was observed for complexes 3 and 4 which were found
especially active against MCF-7 and T-24 cancer cell lines.
The mentioned evident diﬀerences in the antiproliferative
action of the ligand and its diorganotin(VI) complexes
indicate that these complexes really exist under the condition
of the biological tests. Interestingly enough, 3 and 4 were
found to be more potent cytotoxic agent than the prevalent
benchmark metallodrug, cis-platin, under the same experi-
mental conditions measured by us. The superior activity of
3 and 4 assumes signiﬁcance in light of the fact that cis-
platin is undisputedly the most studied and widely used
metallopharmaceutical for cancer therapy known to date. It
is noteworthy the high selectivity against MCF-7 and T-24
cancer cell lines.
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